2022; 20(3): 567-572  
Amisulpride Augmentation in Schizophrenia Patients with Poor Response to Olanzapine: A 4-week, Randomized, Rater-Blind, Controlled, Pilot Study
Young Sup Woo1, Sung-Yong Park2, Bo-Hyun Yoon3, Won-Seok Choi1, Sheng-Min Wang1, Won-Myong Bahk1
1Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, 2Department of Psychiatry, Keyo Hospital, Uiwang, 3Department of Psychiatry, Naju National Hospital, Naju, Korea
Correspondence to: Won-Myong Bahk
Department of Psychiatry, Yeouido St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 10 63-ro, Yeongdeungpo-gu, Seoul 07345, Korea
E-mail: wmbahk@catholic.ac.kr
ORCID: https://orcid.org/0000-0002-0156-2510
Received: April 7, 2021; Accepted: April 30, 2021; Published online: August 31, 2022.
© The Korean College of Neuropsychopharmacology. All rights reserved.

Objective: The purpose of this study was to compare the efficacy and tolerability of continued olanzapine (OLA) versus amisulpride (AMI) augmentation in schizophrenic patients with poor response to OLA monotherapy.
Methods: The present 4-week, randomized, rater-blinded study included 25 patients with schizophrenia who were partially or completely unresponsive to treatment with OLA monotherapy. Eligible subjects were randomly assigned at a 1:1 ratio to continuation of OLA monotherapy (OLA group) or OLA with AMI augmentation (AMI group). Efficacy was primarily evaluated using the Positive and Negative Syndrome Scale (PANSS) at baseline and at 1, 2, and 4 weeks.
Results: The changes in PANSS total score and PANSS-positive subscale score were significantly different (p < 0.05) between the OLA and AMI groups. The differences between the two groups in PANSS-negative subscale, PANSS-general subscale, Brief Psychiatric Rating Scale, and Clinical Global Impression-Severity (CGI-S) scale scores were not statistically significant.
Conclusion: AMI augmentation could be an effective strategy for patients with schizophrenia who show inadequate early response to OLA monotherapy.
Keywords: Amisulpride; Olanzapine; Schizophrenia; Augmentation; Response

Antipsychotic combination treatment or polypharmacy has been widely utilized in clinical practice, although concerns regarding safety, tolerability, and cost-effectiveness are widely recognized [1-3]. Furthermore, several recent results supported that a certain proportion of patients can benefit from antipsychotics polypharmacy without further negative consequences [4].

Olanzapine (OLA) is a common first-prescribed antipsychotic and has shown favorable efficacy in acutely exacerbated patients with schizophrenia [5-7]. The mixed receptor activity of OLA and its greater affinity for serotonin 5-HT2A rather than dopamine D2 receptors are similar to those of clozapine [8,9]. Pharmacokinetically, OLA is metabolized mainly by hepatic cytochrome enzyme P450 1A2 (CYP1A2) [10]. Because risks of antipsychotic polypharmacy include increased drug-drug interactions [11], pharmacokinetic considerations are important for selection of antipsychotics to be combined. Due to its pharmacological characteristics, amisulpride (AMI), another atypical antipsychotic with proven efficacy [6,7,12], is a promising adjuvant agent of special interest. AMI is unlikely to interact with other drugs due to the low plasma protein binding and metabolism and does not affect the activity of the CYP system [13,14]. Furthermore, AMI is highly selective for dopamine D2/D3 receptors; has minimal or no affinity for D1, D4, or D5 receptors [15]. Despite the potential benefits of the combination of OLA and AMI, only a few open-label studies have been conducted [16,17], and no randomized clinical trial has been performed to date to examine the efficacy and tolerability of the combination. Hence, the goals of this study were to test the hypothesis that AMI augmentation would improve psychotic symptoms and be well tolerated in schizophrenic patients who showed poor response to OLA monotherapy.


Study Design and Participants

This open-label, rater-blinded, randomized study was conducted in one university hospital and two psychiatric hospitals in Korea between January 2017 and December 2019. Inpatients or outpatients who met the following criteria were eligible to participate: (1) 19−65 years of age, (2) diagnosis of schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth edition, (3) acute worsening for 3−8 weeks, (4) a Clinical Global Impression-Improvement (CGI-I) score 4 or more (unchanged or worse) despite 1−3 weeks of OLA treatment for the current acute episode, and (5) at least mild severity of symptoms as evidenced by a Positive and Negative Syndrome Scale (PANSS) score of 58 or higher [18]. Subjects were excluded if they had (1) suicidal ideation, (2) comorbid psychiatric disorder other than schizophrenia, (3) unstable comorbid medical conditions, (4) pregnancy or lactation, (5) were prescribed a depot of antipsychotics within 60 days of the study, (6) showed intolerance to OLA or AMI, (7) were prescribed AMI before the study, or (8) showed treatment resistance defined as minimal or no response (< 20% reduction in symptoms) to treatment from at least two adequately dosed (> 600 mg/day of chlorpromazine equivalent) antipsychotic trials over at least 4 weeks [19].


Eligible subjects were randomly assigned at a 1:1 ratio to continuation of OLA treatment (OLA group) or OLA with AMI augmentation (AMI group) for 4 weeks. For both OLA and AMI groups, subjects continued their OLA doses throughout the study. AMI was initiated at a dose of 400 mg/day, and doses were modified at the discretion of the treating clinical psychiatrist within a range of 400−800 mg/day. Concomitant treatment with ongoing benzodiazepines or anti-Parkinsonian drugs was permitted if the patient had been on a stable dose for at least 2 weeks prior to enrollment, but it was requested that the dose not be changed during the study period. Patients were not given any other antipsychotics, mood stabilizers/anticonvulsants, or antidepressants during the study.


Psychiatric symptoms were evaluated using the PANSS, Brief Psychiatric Rating Scale (BPRS), and Clinical Global Impression-Severity (CGI-S) scale at baseline and at 1, 2, and 4 weeks. The primary efficacy assessment was defined as mean change in PANSS total score from baseline to 4 weeks. Additional efficacy measures included response rates with PANSS and BPRS; mean change in PANSS-positivity or negativity, and general subscale, BPRS, and CGI-S scores. Response was defined as a decrease in PANSS and BPRS total scores ≥ 25% [20].

Safety assessments including a physical examination, weight, reported adverse events, the Simpson-Angus Scale (SAS), the Barnes Akathisia Rating Scale (BARS), and the Abnormal Involuntary Movements Scale (AIMS) were performed at each visit. All assessors were blinded to patient condition and prescribed medications.

Statistical Analysis

Data were analyzed for an intent-to-treat group, and the last observation carried forward (LOCF) method was applied for endpoint analysis. The data included all patients who underwent baseline and at least one post-baseline data measurement. All subjects who received at least one dose of the study medication were included in the safety analysis. Data for psychiatric symptom measures and adverse effects rating scales were analyzed using repeated measure analysis of variance (RM-ANOVA). The Greenhouse-Geisser correction was used to test for non-sphericity. The chi-square test or Fisher’s exact test was used to analyze categorical variables, and Mann–Whitney U test was performed to compare baseline values of continuous variables between the OLA and AMI groups. All statistical tests were two-tailed with a significance level of 0.05.


The study protocol, informed consent document, and other study-specific materials were approved by the institutional review committee at Yeouido St. Mary’s Hospital (SC14MCSV0018). Written informed consent was obtained from all subjects after an extensive explanation of the nature and procedures of the study.


Patients and Medications

A total of 25 patients was included and randomized to AMI (n = 13) or OLA group (n = 12); 22 (88.0%) participants completed the 4-week treatment. Two subjects from the OLA group (16.7%) and one subject from the AMI group (7.7%) withdrew from the study prematurely; all causes of study incompletion were lack of efficacy. Significant difference was not observed between the two groups in baseline demographic and clinical characteristics (Table 1). The AMI dose at each visit was 400 mg/day at baseline and 550.0 mg/day at week 4.


The changes in PANSS total score and PANSS-positive subscale score were significantly different (p < 0.05) between the OLA group and AMI group (Fig. 1). The differences between the two groups in PANSS-negative subscale and PANSS-general subscale were not statistically significant (p = 0.055 and p = 0.096, respectively); however, a trend toward greater improvement was observed in the AMI group (Fig. 1).

The numbers of responders who showed reduction of 25% or greater in PANSS and BPRS scores at week 4 were 10 (76.9%) and 12 (92.3%) in the AMI group, respectively, and 4 (33.3%) and 7 (58.3%) in the OLA group. The PANSS response rate was significantly higher in the AMI group on week 2 (p = 0.011) and week 4 (p = 0.047); however, the BPRS response rate was not significantly different between the two groups.

Tolerability and Safety

Two subjects (16.7%) in the OLA group and 5 subjects (38.5%) in AMI group reported adverse events. In the OLA group, akathisia and daytime sedation were reported, and 2 cases of akathisia, 4 cases of extrapyramidal symptoms including rigidity and tremor, 1 case of constipation were reported in the AMI group. The severity of every reported adverse event was mild or moderate.

The RM-ANOVA results showed that the changes in scores on SAS (p = 0.676), BARS (p = 0.129), and AIMS (p = 0.370) during the 4-week study period were not significantly different between the two groups.


In this rater-blinded, open-label study, significantly greater reduction in PANSS total score and PANNS-positive subscale score was observed in the AMI group compared with the OLA group. These results correlate with other previous open-label/retrospective chart review studies in which combination of AMI with OLA or other second-generation antipsychotics reportedly induced symptom improvements measured using global assessment of functioning (GAF), CGI, and BPRS scores in treatment-resistant schizophrenic patients without increasing severe neuroleptic-related side effects [16,17,21]. However, unlike previous studies, significant improvements were not observed in BPRS and CGI-S scores. This difference could be due to the difference in number of items scoring negative symptoms in BPRS and PANSS (3 items vs. 7 items); identifying the difference of negative symptoms before and after treatment can be difficult using BPRS [22]. In addition, PANSS might have greater predictive power than BPRS due to its clearly defined scoring system with severity and frequency of psychiatric symptoms; this difference of sensitivity in each scale might have affected our study results [23].

The present study had limitations that should be considered when interpreting the results. Due to the short study period and limited number of recruited patients, the reduction of PANSS score could be insufficient to show difference in CGI-S score between groups [24]. However, greater difference can be expected after a 4-week study period with ongoing medication. In addition, the numerical difference in PANSS general and negative scores between the AMI and OLA groups was not significant, likely also due to the small sample size. Due to the characteristics of an open-label, prospective study, a control group was not included and might have caused bias. Furthermore, due to the small sample size, generalization of the study results is difficult. In addition, due to our sample exclusion criteria, patients with psychiatric diagnosis other than schizophrenia were excluded. Considering that more than half of schizophrenic patients have comorbid psychiatric disorders, it is difficult to generalize the study results [25]. In addition, common side effects such as elevated prolactin and cardiac markers caused by dopamine blockade of AMI were not evaluated and metabolic parameters such as BMI, weight, triglycerides, and fasting glucose were not assessed.

Despite the short study period and lack of assessment of other drug side effects, the present study results indicated that AMI augmentation was effective and tolerable in schizophrenia patients who showed poor response to OLA monotherapy. The study results confirmed antipsychotic polypharmacy as an alternative treatment option for schizophrenic patients showing lack of efficacy with antipsychotic monotherapy.


This work was supported and funded by Handok Pharmaceuticals, Seoul, Korea.

Conflicts of Interest

No potential conflict of interest relevant to this article was reported.

Author Contributions

Conceptualization: Won-Myong Bahk and Bo-Hyun Yoon. Data acquisition: Young Sup Woo, Sung-Yong Park, Bo-Hyun Yoon, Sheng-Min Wang, and Won-Myong Bahk. Formal analysis: Young Sup Woo, Sung-Yong Park, Sheng-Min Wang, and Won-Seok Choi. Funding: Won-Myong Bahk. Supervision: Won-Myong Bahk. Writing original draft: Young Sup Woo, Sheng-Min Wang, and Won-Seok Choi. Writing review and editing: Sung-Yong Park, Bo-Hyun Yoon, and Won-Myong Bahk.

Fig. 1. Changes of Positive and Negative Syndrome Scale (PANSS) scores, Brief Psychiatric Rating Scale (BPRS) total score, and Clinical Global Impression-Severity (CGI-S) score during the study. OLA, olanzapine; AMI, amisulpride.

Baseline demographic and clinical characteristics

Baseline characteristics Olanzapine (n = 12) Olanzapine + Amisulpride (n = 13) p value
Male 6 (50.0) 6 (46.2) 0.848
Age 46.2 ± 14.0 49.0 ± 10.2 0.703
Inpatient 8 (66.7) 8 (61.5) > 0.999
Married 4 (33.3) 5 (38.5) > 0.999
Living alone 1 (8.3) 1 (7.7) > 0.999
Education 13.6 ± 2.9 13.0 ± 2.1 0.424
Employed 2 (16.7) 2 (15.4) > 0.999
High 0 (0.0) 0 (0.0) > 0.999
Middle 9 (75.0) 9 (69.2)
Low 3 (25.0) 4 (30.8)
Age at onset 35.0 ± 13.7 32.6 ± 7.2 0.870
Duration of illness (mo) 134.0 ± 100.1 196.7 ± 112.6 0.142
Baseline score
PANSS-Positive 26.7 ± 7.0 29.3 ± 5.1 0.353
PANSS-Negative 23.0 ± 5.3 23.3 ± 6.4 0.913
PANSS-General 52.3 ± 7.7 54.8 ± 10.7 0.723
PANSS total score 102.0 ± 11.8 107.5 ± 19.3 0.446
BPRS 39.8 ± 10.3 42.5 ± 11.8 0.785
CGI-Improvement (comparing the time point of olanzapine initiation) 4.8 ± 0.8 4.8 ± 0.9 0.748
CGI-Severity 5.4 ± 0.8 5.0 ± 1.0 0.194
GAF 32.2 ± 13.0 35.0 ± 11.4 0.393
Medication dose (mg/d)
Olanzapine 19.6 ± 6.6 16.9 ± 6.6 0.369
Amisulpride 400

Values are presented as number (%) or mean ± standard deviation.

PANSS, Positive and Negative Syndrome Scale; BPRS, Brief Psychiatric Rating Scale; CGI, Clinical Global Impression; GAF, Global Assessment of Functioning.

  1. Moore BA, Morrissette DA, Meyer JM, Stahl SM. Drug information update. Unconventional treatment strategies for schizophrenia: polypharmacy and heroic dosing. BJPsych Bull 2017;41:164-168.
    Pubmed KoreaMed CrossRef
  2. Pae CU, Han C, Bahk WM, Lee SJ, Patkar AA, Masand PS. Consideration of long-acting injectable antipsychotics for polypharmacy regimen in the treatment of schizophrenia: put it on the table or not? Clin Psychopharmacol Neurosci 2021;19:434-448.
    Pubmed KoreaMed CrossRef
  3. Lee JS, Yun JY, Kang SH, Lee SJ, Choi JH, Nam B, et al. Korean Medication Algorithm for Schizophrenia 2019, second revision: treatment of psychotic symptoms. Clin Psychopharmacol Neurosci 2020;18:386-394.
    Pubmed KoreaMed CrossRef
  4. Lin SK. Antipsychotic polypharmacy: a dirty little secret or a fashion? Int J Neuropsychopharmacol 2020;23:125-131.
    Pubmed KoreaMed CrossRef
  5. Roh D, Chang JG, Yoon S, Kim CH. Antipsychotic prescribing patterns in first-episode schizophrenia: a five-year com-parison. Clin Psychopharmacol Neurosci 2015;13:275-282.
    Pubmed KoreaMed CrossRef
  6. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013;382:951-962.
    Pubmed CrossRef
  7. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009;373:31-41.
    Pubmed CrossRef
  8. Bhana N, Foster RH, Olney R, Plosker GL. Olanzapine: an updated review of its use in the management of schizophrenia. Drugs 2001;61:111-161.
    Pubmed CrossRef
  9. Aringhieri S, Carli M, Kolachalam S, Verdesca V, Cini E, Rossi M, et al. Molecular targets of atypical antipsychotics: from mechanism of action to clinical differences. Pharmacol Ther 2018;192:20-41.
    Pubmed CrossRef
  10. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet 1999;37:177-193.
    Pubmed CrossRef
  11. Gibson AP, Patel NC, Lauriello J, Buckley PF. Antipsychotic combinations: blind step or logical? T Though unsupported by evidence, using >1 antipsychotic may make sense for some treatment-resistant patients. Curr Psychiatry 2008;7:41-53.
  12. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008;371:1085-1097.
    Pubmed CrossRef
  13. Rosenzweig P, Canal M, Patat A, Bergougnan L, Zieleniuk I, Bianchetti G. A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers. Hum Psychopharmacol 2002;17:1-13.
    Pubmed CrossRef
  14. Mauri MC, Paletta S, Di Pace C, Reggiori A, Cirnigliaro G, Valli I, et al. Clinical pharmacokinetics of atypical antipsychotics: an update. Clin Pharmacokinet 2018;57:1493-1528.
    Pubmed KoreaMed CrossRef
  15. Perrault G, Depoortere R, Morel E, Sanger DJ, Scatton B. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity. J Pharmacol Exp Ther 1997;280:73-82.
  16. Zink M, Henn FA, Thome J. Combination of amisulpride and olanzapine in treatment-resistant schizophrenic psychoses. Eur Psychiatry 2004;19:56-58.
    Pubmed CrossRef
  17. Molina JD, Toledo-Romero F, López-Rodríguez E, Amorin-Díaz M, Lerma-Carrillo I, López-Muñoz F. Augmentation treatment with amisulpride in schizophrenic patients partially responsive to olanzapine. Pharmacopsychiatry 2011;44:142-147.
    Pubmed CrossRef
  18. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean? Schizophr Res 2005;79:231-238.
    Pubmed CrossRef
  19. Kane JM, Honigfeld G, Singer J, Meltzer H. Clozapine in treatment-resistant schizophrenics. Psychopharmacol Bull 1988;24:62-67.
    Pubmed CrossRef
  20. Leucht S, Davis JM, Engel RR, Kissling W, Kane JM. Definitions of response and remission in schizophrenia: recommendations for their use and their presentation. Acta Psychiatr Scand Suppl 2009;438:7-14.
    Pubmed CrossRef
  21. Kang SG, Cho SE, Na KS, Pae CU, Cho SJ. Clinical usefulness of amisulpride add-on therapy in schizophrenia patients without treatment response to second-generation antipsychotics. Clin Psychopharmacol Neurosci 2021;19:117-124.
    Pubmed KoreaMed CrossRef
  22. Mortimer AM. Symptom rating scales and outcome in schizophrenia. Br J Psychiatry Suppl 2007;50:s7-s14.
    Pubmed CrossRef
  23. Bell M, Milstein R, Beam-Goulet J, Lysaker P, Cicchetti D. The Positive and Negative Syndrome Scale and the Brief Psychiatric Rating Scale. Reliability, comparability, and predictive validity. J Nerv Ment Dis 1992;180:723-728.
    Pubmed CrossRef
  24. Leucht S, Kane JM, Etschel E, Kissling W, Hamann J, Engel RR. Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacology 2006;31:2318-2325.
    Pubmed CrossRef
  25. Goldman LS. Medical illness in patients with schizophrenia. J Clin Psychiatry 1999;60 Suppl 21:10-15.

This Article

Cited By Articles
  • CrossRef (0)

Author ORCID Information

Social Network Service